IL160363A0 - Expandable gastric retention device - Google Patents

Expandable gastric retention device

Info

Publication number
IL160363A0
IL160363A0 IL16036301A IL16036301A IL160363A0 IL 160363 A0 IL160363 A0 IL 160363A0 IL 16036301 A IL16036301 A IL 16036301A IL 16036301 A IL16036301 A IL 16036301A IL 160363 A0 IL160363 A0 IL 160363A0
Authority
IL
Israel
Prior art keywords
retention device
gastric retention
expandable gastric
expandable
retention
Prior art date
Application number
IL16036301A
Other languages
English (en)
Original Assignee
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State filed Critical Oregon State
Publication of IL160363A0 publication Critical patent/IL160363A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0409Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0409Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414Particles, beads, capsules or spheres
    • A61K49/0419Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL16036301A 2001-08-16 2001-10-22 Expandable gastric retention device IL160363A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31307801P 2001-08-16 2001-08-16
PCT/US2001/046146 WO2003015745A1 (fr) 2001-08-16 2001-10-22 Dispositif de retention gastrique expansible

Publications (1)

Publication Number Publication Date
IL160363A0 true IL160363A0 (en) 2004-07-25

Family

ID=23214285

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16036301A IL160363A0 (en) 2001-08-16 2001-10-22 Expandable gastric retention device

Country Status (14)

Country Link
EP (1) EP1416914A1 (fr)
JP (1) JP2005501097A (fr)
KR (1) KR20040032918A (fr)
CN (1) CN1543337A (fr)
BR (1) BR0117123A (fr)
CA (1) CA2456976A1 (fr)
CO (1) CO5670360A2 (fr)
IL (1) IL160363A0 (fr)
MX (1) MXPA04001388A (fr)
NO (1) NO20040611L (fr)
NZ (1) NZ531461A (fr)
PL (1) PL368327A1 (fr)
WO (1) WO2003015745A1 (fr)
ZA (1) ZA200402066B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365395B2 (en) 2001-11-21 2006-07-20 Bracco Diagnostics Inc. Formulations for use in medical or diagnostic procedures
JP2007517039A (ja) * 2003-12-24 2007-06-28 アドバンシス ファーマスーティカル コーポレイション 変性放出製剤の吸収増強
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7699863B2 (en) 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
WO2008011496A2 (fr) * 2006-07-19 2008-01-24 Smithkline Beecham Corporation Procédé de radiomarquage de formulations pour l'évaluation par scintigraphie gamma
CN102552103B (zh) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
US10507127B2 (en) 2012-06-07 2019-12-17 Epitomee Medical Ltd. Expandable device
BR112016012615B1 (pt) 2013-12-05 2023-02-07 Epitomee Medical Ltd Sistemas, e kit
BR122021018078B1 (pt) 2014-06-11 2022-02-08 Massachusetts Institute Of Technology Artigo e estrutura de residência gástrica
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
JP2018515476A (ja) 2015-05-01 2018-06-14 マサチューセッツ インスティテュート オブ テクノロジー 誘発性形状記憶誘導デバイス
US11576859B2 (en) 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CA3007633A1 (fr) 2015-12-08 2017-06-15 Lyndra, Inc. Configurations geometriques de systemes a residence gastrique
CA3038557A1 (fr) 2016-09-30 2018-04-05 Lyndra, Inc. Systemes de residence gastrique permettant l'administration prolongee de medicaments de la classe de l'adamantane
CN110996906A (zh) 2017-06-09 2020-04-10 林德拉有限公司 具有调节释放速度的膜的胃驻留系统
JP2021506984A (ja) * 2017-12-18 2021-02-22 トリス・フアルマ・インコーポレーテツド トリガーパルス薬物放出を有する胃内滞留型raft形成システムを含む放出調節薬物粉末組成物
TR201914116A2 (tr) * 2019-09-17 2021-04-21 Univ Yeditepe Doğal bi̇yomateryaller i̇le kri̇yojelleri̇n üreti̇m yöntemi̇ ve bu kri̇yojelleri̇n yumuşak doku i̇skelesi̇ veya i̇laç taşiyici si̇stem olarak kullanimi
WO2022195476A1 (fr) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Dispositifs de rétention gastrique pour l'évaluation d'états intragastriques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
EP1003476B1 (fr) * 1997-08-11 2004-12-22 ALZA Corporation Forme galenique d'un agent actif a liberation prolongee adaptee a la retention gastrique
PL346798A1 (en) * 1998-09-14 2002-02-25 Ranbaxy Lab Ltd Orally administered controlled drug delivery system providing temporal and spatial control
JP2000256216A (ja) * 1999-03-04 2000-09-19 Meiji Milk Prod Co Ltd ゲル組成物
AU6872201A (en) * 2000-06-23 2002-01-08 Teva Pharma Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Also Published As

Publication number Publication date
CA2456976A1 (fr) 2003-02-27
ZA200402066B (en) 2005-05-09
EP1416914A1 (fr) 2004-05-12
NZ531461A (en) 2008-03-28
KR20040032918A (ko) 2004-04-17
BR0117123A (pt) 2004-09-28
NO20040611L (no) 2004-04-16
CO5670360A2 (es) 2006-08-31
MXPA04001388A (es) 2004-05-27
PL368327A1 (en) 2005-03-21
JP2005501097A (ja) 2005-01-13
WO2003015745A1 (fr) 2003-02-27
CN1543337A (zh) 2004-11-03

Similar Documents

Publication Publication Date Title
HK1070532A1 (en) Expandable in-ear device
GB0107858D0 (en) Device
IL160363A0 (en) Expandable gastric retention device
SG101984A1 (en) Deplexer device
EP1379079A4 (fr) Dispositif d'accentuation de contour
GB2371229B (en) De-odourising device
GB2376781B (en) Memory device
GB0111329D0 (en) Device
GB0202445D0 (en) Device
GB0111328D0 (en) Device
GB0111336D0 (en) Device
GB2376720B (en) Fluid-propelling device
GB2378421B (en) Multi-embossing device
GB0111330D0 (en) Device
GB0110166D0 (en) Shock-shower device
GB0111337D0 (en) Device
GB0114945D0 (en) Device
GB2383317B (en) Mooring device
GB0104001D0 (en) Gastric drainage device
GB0116785D0 (en) Mediical Device
TW461332U (en) Leg-lifting device
GB0117190D0 (en) Memory device
GB0112011D0 (en) Memory Device
AU146292S (en) Anchoring device
GB0113948D0 (en) Restraining device